

# MENINGOCOCCAL VACCINE FACT SHEET

## (MCV4 and SEROGROUP B)



**Brand Name/  
Manufacturer**

**Menactra  
Sanofi Pastuer**

**Menveo  
Novartis**

**Trumenba  
Pfizer**

**Bexsero  
Novartis**

**Protects  
Against**

Invasive Meningococcal Disease caused by Neisseria Meningitidis A, C, W and Y-135

Invasive Meningococcal Disease caused by Neisseria Meningitidis A, C, W and Y-135

Invasive Meningococcal Disease caused by Neisseria Meningitidis Serogroup B

Invasive Meningococcal Disease caused by Neisseria Meningitidis Serogroup B

**Approved for  
use in**

Persons 9 months through 55 years

Persons 2 months to 55 years

Persons 10 through 25 years (10 through 18 years if using vaccine supplied through the Maine Immunization Program)

Persons 10 through 25 years (10 through 18 years if using vaccine supplied through the Maine Immunization Program)

**Routine  
Schedule**

One (1) dose at 11-12 years and one (1) booster dose at 16 years

One (1) dose at 11-12 years and one (1) booster dose at 16 years

**Not routinely recommended but could be offered to high risk patients** 10 through 25 years old (10 through 18 years if using state supplied vaccine).

**Not routinely recommended but could be offered to high risk patients** 10 through 25 years old (10 through 18 years if using state supplied vaccine)

Dosing: Three (3) doses given on a 0-, 2-, 6- month schedule

Dosing: Two (2) doses separated by 1 month

**Minimum  
Intervals**

8 week minimum interval between doses

8 week minimum interval between doses

8 week minimum interval between doses

8 week minimum interval between doses

**Comments**

Interchangeable with Menveo after 9 months of age

Interchangeable with Menactra

Can not be interchanged with Bexsero, Menactra, or Menveo

Can not be interchanged with Trumenba, Menactra or Menveo

Can be given concomitantly with the MCV4

Can be given concomitantly with the MCV4